Cargando…

Three-dimensional template combined with MR-guided iodine-125 brachytherapy for recurrent brain metastases

PURPOSE: Treatment of recurrent brain metastases is extremely challenging. Here, we evaluated the feasibility and efficacy of an individualized three-dimensional template combined with MR-guided iodine-125 ((125)I) brachytherapy in the treatment of recurrent brain metastases. MATERIAL AND METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xiangmeng, Xu, Yujun, Liu, Ming, Fang, Jing, Zhang, Kai, Guo, Xiaotong, Yan, Xingchang, Li, Chengli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324592/
https://www.ncbi.nlm.nih.gov/pubmed/37425207
http://dx.doi.org/10.5114/jcb.2023.129055
_version_ 1785069178685751296
author He, Xiangmeng
Xu, Yujun
Liu, Ming
Fang, Jing
Zhang, Kai
Guo, Xiaotong
Yan, Xingchang
Li, Chengli
author_facet He, Xiangmeng
Xu, Yujun
Liu, Ming
Fang, Jing
Zhang, Kai
Guo, Xiaotong
Yan, Xingchang
Li, Chengli
author_sort He, Xiangmeng
collection PubMed
description PURPOSE: Treatment of recurrent brain metastases is extremely challenging. Here, we evaluated the feasibility and efficacy of an individualized three-dimensional template combined with MR-guided iodine-125 ((125)I) brachytherapy in the treatment of recurrent brain metastases. MATERIAL AND METHODS: Twenty-eight patients with recurrent 38 brain metastases underwent (125)I brachytherapy from December, 2017 to January, 2021. A pre-treatment brachytherapy plan and three-dimensional template were generated according to isovoxel T1-weighted MR images. (125)I seeds were implanted under the guidance of three-dimensional template and 1.0-T open MR imaging. Dosimetry verification was performed based on CT/MR fusion images. Pre-operative and post-operative dosimetry parameters of D(90), V(100), and conformity index (CI) were compared. Overall response rate (ORR), disease control rate (DCR) at 6 months, and 1-year survival rate were calculated. Median overall survival (OS) measured from the date of (125)I brachytherapy was estimated using Kaplan-Meier method. RESULTS: No significant differences were observed between pre-operative and post-operative D(90), V(100), and CI values (p > 0.05). The ORR and DCR at 6 months were 91.3% and 95.7%, respectively. The 1-year survival rate was 57.1%. The median OS was 14.1 months. Two cases of minor hemorrhage and 5 cases of symptomatic brain edema were observed during the study. All clinical symptoms were alleviated after corticosteroid treatment applied for 7 to 14 days. CONCLUSIONS: A three-dimensional template combined with MR-guided (125)I brachytherapy in the treatment of recurrent brain metastases is feasible, safe, and effective. This novel (125)I brachytherapy strategy is an attractive alternative in the treatment of brain metastases.
format Online
Article
Text
id pubmed-10324592
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-103245922023-07-07 Three-dimensional template combined with MR-guided iodine-125 brachytherapy for recurrent brain metastases He, Xiangmeng Xu, Yujun Liu, Ming Fang, Jing Zhang, Kai Guo, Xiaotong Yan, Xingchang Li, Chengli J Contemp Brachytherapy Original Paper PURPOSE: Treatment of recurrent brain metastases is extremely challenging. Here, we evaluated the feasibility and efficacy of an individualized three-dimensional template combined with MR-guided iodine-125 ((125)I) brachytherapy in the treatment of recurrent brain metastases. MATERIAL AND METHODS: Twenty-eight patients with recurrent 38 brain metastases underwent (125)I brachytherapy from December, 2017 to January, 2021. A pre-treatment brachytherapy plan and three-dimensional template were generated according to isovoxel T1-weighted MR images. (125)I seeds were implanted under the guidance of three-dimensional template and 1.0-T open MR imaging. Dosimetry verification was performed based on CT/MR fusion images. Pre-operative and post-operative dosimetry parameters of D(90), V(100), and conformity index (CI) were compared. Overall response rate (ORR), disease control rate (DCR) at 6 months, and 1-year survival rate were calculated. Median overall survival (OS) measured from the date of (125)I brachytherapy was estimated using Kaplan-Meier method. RESULTS: No significant differences were observed between pre-operative and post-operative D(90), V(100), and CI values (p > 0.05). The ORR and DCR at 6 months were 91.3% and 95.7%, respectively. The 1-year survival rate was 57.1%. The median OS was 14.1 months. Two cases of minor hemorrhage and 5 cases of symptomatic brain edema were observed during the study. All clinical symptoms were alleviated after corticosteroid treatment applied for 7 to 14 days. CONCLUSIONS: A three-dimensional template combined with MR-guided (125)I brachytherapy in the treatment of recurrent brain metastases is feasible, safe, and effective. This novel (125)I brachytherapy strategy is an attractive alternative in the treatment of brain metastases. Termedia Publishing House 2023-06-30 2023-06 /pmc/articles/PMC10324592/ /pubmed/37425207 http://dx.doi.org/10.5114/jcb.2023.129055 Text en Copyright © 2023 Termedia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
He, Xiangmeng
Xu, Yujun
Liu, Ming
Fang, Jing
Zhang, Kai
Guo, Xiaotong
Yan, Xingchang
Li, Chengli
Three-dimensional template combined with MR-guided iodine-125 brachytherapy for recurrent brain metastases
title Three-dimensional template combined with MR-guided iodine-125 brachytherapy for recurrent brain metastases
title_full Three-dimensional template combined with MR-guided iodine-125 brachytherapy for recurrent brain metastases
title_fullStr Three-dimensional template combined with MR-guided iodine-125 brachytherapy for recurrent brain metastases
title_full_unstemmed Three-dimensional template combined with MR-guided iodine-125 brachytherapy for recurrent brain metastases
title_short Three-dimensional template combined with MR-guided iodine-125 brachytherapy for recurrent brain metastases
title_sort three-dimensional template combined with mr-guided iodine-125 brachytherapy for recurrent brain metastases
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324592/
https://www.ncbi.nlm.nih.gov/pubmed/37425207
http://dx.doi.org/10.5114/jcb.2023.129055
work_keys_str_mv AT hexiangmeng threedimensionaltemplatecombinedwithmrguidediodine125brachytherapyforrecurrentbrainmetastases
AT xuyujun threedimensionaltemplatecombinedwithmrguidediodine125brachytherapyforrecurrentbrainmetastases
AT liuming threedimensionaltemplatecombinedwithmrguidediodine125brachytherapyforrecurrentbrainmetastases
AT fangjing threedimensionaltemplatecombinedwithmrguidediodine125brachytherapyforrecurrentbrainmetastases
AT zhangkai threedimensionaltemplatecombinedwithmrguidediodine125brachytherapyforrecurrentbrainmetastases
AT guoxiaotong threedimensionaltemplatecombinedwithmrguidediodine125brachytherapyforrecurrentbrainmetastases
AT yanxingchang threedimensionaltemplatecombinedwithmrguidediodine125brachytherapyforrecurrentbrainmetastases
AT lichengli threedimensionaltemplatecombinedwithmrguidediodine125brachytherapyforrecurrentbrainmetastases